Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Man triggers smoke bomb during failed crypto robbery - 2Meet the astronauts about to make history on flight around the moon
- 3In these U.S. groups, deaths now exceed births. What’s happening?
- 4Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme
- 5Desired Travel Objections Worldwide: Where to Go Straightaway
- Share your pick for the tree that you love for its novel magnificence!
- Eurasian cargo hub expands to capture Europe-Asia freight flows
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- Getting Your Youngsters' Future: Grasping Legacy Regulations
- Dominating Capable Mastercard Utilization: Key Contemplations
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- Land Rover Just Unveiled Its Dakar Rally Defender
- Astronauts on the ISS watched NASA's historic Artemis 2 launch from space
